Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of oxaliplatin + pemetrexed as second-line therapy in advanced pancreatic cancer
2006-001272-21Phase 2Completed
- Sponsor
- Azienda Ospedaliero-Universitaria di Udine
- Start
- May 2007
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed and oxaliplatin in pancreatic cancer (PC), sponsored by Azienda Ospedaliero-Universitaria di Udine. Primary endpoint: Overall response rate. Started May 2007; status: completed.
02
Drugs
pemetrexedoxaliplatin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2006-001272-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001272-21.